Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

By J. Reginster, H. Minne, O. Sørensen, M. Hooper, C. Roux, M. Brandi, B. Lund, D. Ethgen, S. Pack, I. Roumagnac and 2 more. Osteoporosis International, 2000

1,657 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/d6e3effda8cc945d376394902716a862b2ebc967

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Kanis
2. Chris Cooper
3. R. Rizzoli
4. J. Reginster
5. on behalf of the International Osteoporosis Foundation
6. R. Russell

In Oncology

1. J. Reginster
2. Chris Cooper
3. R. Rizzoli
4. on behalf of the International Osteoporosis Foundation
5. J. Kanis
6. Nelson B. Watts
7. R. Russell

In Orthopedics and Sports Medicine

1. Chris Cooper
2. J. Reginster
3. R. Rizzoli
4. on behalf of the International Osteoporosis Foundation
5. J. Kanis
6. P. Delmas
7. Nelson B. Watts
8. Eugene V. McCloskey

Citations in the corpus

• Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis (2004, background): “After 3 years, the relative risk reduction in new vertebral fractures observed with oral daily alendronate (5–10 mg) and risedronate (5 mg) in phase III pivotal trials was up to 50%((33)) and 49%,((36)) respectively, compared with 62% and 50% with oral daily and intermittent ibandronate, respectivel”